McDavid Stilwell - 04 Jan 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: Chief Financial Officer
Signature: /s/ McDavid Stilwell
Issuer symbol: CHRS
Transactions as of: 04 Jan 2023
Net transactions value: -$53,663
Form type: 4
Filing time: 06 Jan 2023, 17:14:54 UTC
Previous filing: 05 Apr 2022
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CHRS	Common Stock	Tax liability	$53,663	-5,437	-7.8%	$9.87	64,243	04 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+80,000		$0.000000	80,000	04 Jan 2023	Common Stock	80,000	$9.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2	The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.